MA43515A - Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll - Google Patents

Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll

Info

Publication number
MA43515A
MA43515A MA043515A MA43515A MA43515A MA 43515 A MA43515 A MA 43515A MA 043515 A MA043515 A MA 043515A MA 43515 A MA43515 A MA 43515A MA 43515 A MA43515 A MA 43515A
Authority
MA
Morocco
Prior art keywords
menin
inhibiting
interaction
compositions
methods
Prior art date
Application number
MA043515A
Other languages
English (en)
Inventor
Dmitry Borkin
Tomasz Cierpicki
Jun Feng
Jolanta Grembecka
Szymon Klossowski
Liansheng Li
Yi Liu
Jonathan Pollock
Pingda Ren
Tao Wu
Original Assignee
Kura Oncology Inc
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc, Univ Michigan Regents filed Critical Kura Oncology Inc
Publication of MA43515A publication Critical patent/MA43515A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
MA043515A 2015-06-04 2016-03-16 Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll MA43515A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171108P 2015-06-04 2015-06-04
ARP160100689A AR104020A1 (es) 2015-06-04 2016-03-15 Métodos y composiciones para inhibir la interacción de menina con proteínas mill

Publications (1)

Publication Number Publication Date
MA43515A true MA43515A (fr) 2021-05-19

Family

ID=58608916

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043515A MA43515A (fr) 2015-06-04 2016-03-16 Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll

Country Status (21)

Country Link
US (3) US10077271B2 (fr)
EP (2) EP4006030A3 (fr)
JP (1) JP6730321B2 (fr)
KR (1) KR102626673B1 (fr)
CN (3) CN116217581A (fr)
AR (1) AR104020A1 (fr)
AU (1) AU2016270002B2 (fr)
CA (1) CA2985053C (fr)
DK (1) DK3303317T3 (fr)
EA (1) EA035141B1 (fr)
ES (1) ES2902501T3 (fr)
IL (1) IL255701B (fr)
MA (1) MA43515A (fr)
MX (1) MX382545B (fr)
MY (1) MY186712A (fr)
PH (1) PH12017502188B1 (fr)
PL (1) PL3303317T3 (fr)
PT (1) PT3303317T (fr)
TW (1) TWI703150B (fr)
WO (1) WO2016195776A1 (fr)
ZA (1) ZA201707848B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (fr) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
MX387806B (es) 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
EP3429591B1 (fr) 2016-03-16 2023-03-15 Kura Oncology, Inc. Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation
KR20190015275A (ko) 2016-05-02 2019-02-13 더 리젠츠 오브 더 유니버시티 오브 미시간 메닌 억제제로서의 피페리딘
WO2017207387A1 (fr) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EP3512858B1 (fr) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Inhibiteur bicyclique fusionné d'interaction menin-mll
ES2872003T3 (es) 2016-09-14 2021-11-02 Janssen Pharmaceutica Nv Inhibidores espirobicíclicos de la interacción de menina-MLL
KR102513564B1 (ko) * 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
WO2018172984A1 (fr) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
AU2018239798B2 (en) * 2017-03-23 2020-08-27 Daegu Gyeongbuk Institute Of Science And Technology Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
EP3601249A4 (fr) * 2017-03-24 2020-12-16 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
KR20190133224A (ko) 2017-03-31 2019-12-02 더 리젠츠 오브 더 유니버시티 오브 미시간 공유 메닌 억제제로서의 피페리딘
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2018228923A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués utilisés en tant que modulateurs de map4k1 pour le traitement de maladies cancéreuses
CA3066859A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Derives de pyrrolopyridine substitues
WO2018228925A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués
US11427578B1 (en) 2017-07-18 2022-08-30 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
JP7307729B2 (ja) * 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
EP4600247A3 (fr) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Inhibiteurs de pd-1/pd-l1
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
MX2021006696A (es) * 2018-12-06 2021-07-07 Daiichi Sankyo Co Ltd Derivado de cicloalcano-1,3-diamina.
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CA3168211A1 (fr) 2019-01-18 2020-07-23 Voronoi Co., Ltd. Derive de pyrrolopyridine et son utilisation dans la prevention et le traitement d'une maladie liee a la proteine kinase
ES2987269T3 (es) * 2019-09-20 2024-11-14 Novartis Ag Inhibidores de MLL1 y agentes anticancerígenos
TWI878414B (zh) 2019-12-19 2025-04-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
WO2021249913A1 (fr) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer
WO2022086986A1 (fr) * 2020-10-21 2022-04-28 Kura Oncology, Inc. Traitement de malignités hématologiques par des inhibiteurs de ménine
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
CA3202330A1 (fr) * 2020-12-16 2022-06-23 Anthony Casarez Composes utiles en tant qu'activateurs de lymphocytes t
US20240174683A1 (en) 2021-02-05 2024-05-30 Bayer Aktiengesellschaft Map4k1 inhibitors
CA3213079A1 (fr) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Heterocycles amino-substitues pour le traitement de cancers avec des mutations egfr
WO2022237626A1 (fr) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Dérivés spiro substitués
AU2022275192A1 (en) 2021-05-08 2024-01-04 Janssen Pharmaceutica Nv Substituted spiro derivatives
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
PH12023553300A1 (en) 2021-06-17 2024-04-08 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (fr) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 Nouvel inhibiteur de l'interaction de la ménine-mll, son procédé de préparation et son utilisation médicale
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2024015478A2 (fr) * 2022-07-14 2024-01-18 Huyabio International, Llc Polythérapies associant des inhibiteurs de wdr5 et des inhibiteurs de pd-1
WO2024110649A1 (fr) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinaisons d'inhibiteurs de lsd1 et d'inhibiteurs de ménine pour le traitement du cancer
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
AU2024292586A1 (en) 2023-07-17 2026-01-29 Kura Oncology, Inc. Crystalline forms of a menin inhibitor
WO2025016385A1 (fr) 2023-07-17 2025-01-23 Kura Oncology, Inc. Compositions pharmaceutiques comprenant un inhibiteur de ménine
WO2025044946A1 (fr) * 2023-08-25 2025-03-06 武汉人福创新药物研发中心有限公司 Composé agissant en tant qu'antagoniste de mrgprx2, son procédé de préparation et son utilisation
WO2025232874A1 (fr) * 2024-05-10 2025-11-13 Kura Oncology, Inc. Procédé de fabrication d'un inhibiteur de ménine-mll

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510A (en) 1837-12-07 soeel
US5861A (en) 1848-10-17 Locking umbrella and parasol
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US5863A (en) 1848-10-17 Matthias p
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
CA2260898C (fr) 1996-07-18 2002-05-14 Pfizer Limited Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
DE69730151T2 (de) 1997-01-06 2005-08-04 Pfizer Inc. Cyclische sulfonderivate
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2279863A1 (fr) 1997-02-07 1998-08-13 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
WO1998034918A1 (fr) 1997-02-11 1998-08-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP4310109B2 (ja) 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
CN101100472A (zh) 2001-04-30 2008-01-09 美国拜尔公司 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
AU2003258662A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
NZ542236A (en) 2003-03-31 2008-05-30 Predix Pharmaceuticals Holding New piperidinylamino-thieno[2,3-d]pyrimidine compounds
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
CA2535265C (fr) 2003-08-22 2014-01-28 Dendreon Corporation Compositions et methodes permettant de traiter une maladie associee a l'expression de trp-p8
US20050123906A1 (en) 2003-11-06 2005-06-09 Rana Tariq M. Protein modulation
CN101031551A (zh) 2004-07-06 2007-09-05 安吉永生物制药公司 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂
WO2006132914A2 (fr) 2005-06-03 2006-12-14 Abbott Laboratories Derives de cyclobutyl amine
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
RU2008112661A (ru) 2005-09-02 2009-10-10 Тиботек Фармасьютикалз Лтд. (Ie) Бензодиазепины в качестве ингибиторов hcv
JP5302883B2 (ja) 2006-04-07 2013-10-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン
WO2008070303A2 (fr) 2006-10-19 2008-06-12 The University Of Chicago Agents thérapeutiques permettant d'inhiber l'interaction mll-ménine pour traiter une leucémie
EP1947103A1 (fr) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, procédés de préparation correspondant et utilisation d'aryloxypropanolamines en tant que médicaments
WO2008099019A1 (fr) 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 6-hydroxy-dibenzodiazépinones utiles comme inhibiteurs du virus de l'hépatite c
FR2913017A1 (fr) 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
WO2008114275A2 (fr) 2007-03-19 2008-09-25 Council Of Scientific & Industrial Research Nouveau dérivé de l'acide anthranilique comme anticancéreux potentiel et procédé de préparation de celui-ci
WO2008135232A1 (fr) * 2007-05-02 2008-11-13 Riccardo Cortese Utilisation et compositions de dérivés de purine pour le traitement de troubles prolifératifs
US20080293699A1 (en) 2007-05-25 2008-11-27 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
WO2009017838A2 (fr) 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
WO2009064388A2 (fr) 2007-11-09 2009-05-22 Liu Jun O Inhibiteurs de la méthionine aminopeptidase humaine 1 et procédés de traitement de troubles
WO2009078999A1 (fr) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Modulateurs imidazolo-, oxazolo- et thiazolopyrimidines de trpv1
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20100063047A1 (en) 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
BR112012000422A2 (pt) 2009-07-08 2017-05-09 Leo Pharma As composto, composição farmacêutica, uso de um composto, e, método para a prevenir tratar ou melhorar doenças do sistema imune
US8993552B2 (en) * 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
GB201217704D0 (en) * 2012-10-03 2012-11-14 Ucb Pharma Sa Therapeutic agents
WO2014135480A1 (fr) * 2013-03-06 2014-09-12 Bayer Pharma Aktiengesellschaft Thiazolopyrimidines substituées
US9216993B2 (en) * 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
RU2016141934A (ru) 2014-04-04 2018-05-07 Сирос Фармасьютикалз, Инк. Ингибиторы циклин-зависимой киназы 7 (cdk7)
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2016040330A1 (fr) * 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
CN108779116A (zh) 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
EP3407884B1 (fr) 2016-01-26 2025-07-09 Memorial Sloan-Kettering Cancer Center Ciblage des régulateurs de la chromatine pour inhiber l'expression génique leucémogénique en npm1
EP3429591B1 (fr) 2016-03-16 2023-03-15 Kura Oncology, Inc. Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation
MX387806B (es) 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
KR20190015275A (ko) 2016-05-02 2019-02-13 더 리젠츠 오브 더 유니버시티 오브 미시간 메닌 억제제로서의 피페리딘
WO2017207387A1 (fr) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1
KR102916887B1 (ko) 2016-06-10 2026-01-22 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (fr) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro [4,4] nonanes
EP3512858B1 (fr) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Inhibiteur bicyclique fusionné d'interaction menin-mll
TWI738864B (zh) 2016-09-14 2021-09-11 比利時商健生藥品公司 Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑
JP2019529421A (ja) 2016-09-16 2019-10-17 ヴァイティー ファーマシューティカルズ，エルエルシー ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤

Also Published As

Publication number Publication date
US20180327414A1 (en) 2018-11-15
ZA201707848B (en) 2022-04-28
US10077271B2 (en) 2018-09-18
JP2018516888A (ja) 2018-06-28
JP6730321B2 (ja) 2020-07-29
KR102626673B1 (ko) 2024-01-18
EA201792583A1 (ru) 2018-07-31
EP3303317A4 (fr) 2018-11-07
MX382545B (es) 2025-03-13
ES2902501T3 (es) 2022-03-28
BR112017026085A2 (pt) 2018-08-14
TW201704241A (zh) 2017-02-01
TWI703150B (zh) 2020-09-01
US10174041B2 (en) 2019-01-08
IL255701B (en) 2020-06-30
EP3303317B1 (fr) 2021-10-06
CN121800804A (zh) 2026-04-07
CA2985053A1 (fr) 2016-12-08
AU2016270002B2 (en) 2020-08-27
US20250304589A1 (en) 2025-10-02
WO2016195776A1 (fr) 2016-12-08
IL255701A (en) 2018-01-31
MX2017015467A (es) 2018-04-10
EP4006030A3 (fr) 2022-06-22
AU2016270002A1 (en) 2017-12-21
HK1246298A1 (en) 2018-09-07
PH12017502188B1 (en) 2023-01-11
CN116217581A (zh) 2023-06-06
NZ738015A (en) 2024-04-26
KR20180021780A (ko) 2018-03-05
PT3303317T (pt) 2022-01-05
CA2985053C (fr) 2023-09-19
PL3303317T3 (pl) 2022-04-04
EP3303317A1 (fr) 2018-04-11
EP4006030A2 (fr) 2022-06-01
PH12017502188A1 (en) 2018-06-04
MY186712A (en) 2021-08-12
DK3303317T3 (da) 2021-12-13
AR104020A1 (es) 2017-06-21
US20180105531A1 (en) 2018-04-19
CN107922378A (zh) 2018-04-17
EA035141B1 (ru) 2020-05-06

Similar Documents

Publication Publication Date Title
ZA201707848B (en) Methods and compositions for inhibiting the interaction of menin with mll proteins
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
EP3302057A4 (fr) Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP3518934A4 (fr) Inhibiteurs de l'adénosine 5'-nucléotidase
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
SI3352584T1 (sl) Sestavki in postopki za sintezo 5'-omejenih RNAjev
MA46180A (fr) Analogues de l'amyline
MA71266A (fr) Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
MA71468A (fr) Compositions et méthodes pour diminuer l'expression de tau
EP3407884A4 (fr) Inhibition de l'expression génique leucémogénique dans la leucémie mutantenpm1
MA41901A (fr) Compositions contenant de l'ibrutinib
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
EP3349743A4 (fr) Procédés et compositions d'inhibition de l'interaction dcn1-ubc12
EP3426242A4 (fr) Icaritine et dérivés d'icaritine
EP3699245A4 (fr) Assortiment d'encres
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
MA46717A (fr) Variantes de l'endonucléase homing tcra
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3449001A4 (fr) Inhibition de l'arnmi mir-22 par apt-110
EP3339376A4 (fr) Composition d'additif de résine et composition de résine synthétique l'utilisant
EP3463259A4 (fr) Compositions d'écran solaire
EP3426349A4 (fr) Procédés et compositions pour inhiber l'expression de pmp22
EP3512839A4 (fr) Inhibiteurs de yap1 ciblant l'interaction de yap1 avec oct4
MA46641A (fr) Méthodes et compositions permettant d'empêcher la transmission de maladies propagées par un vecteur